Perbak Capital Partners LLP Lowers Holdings in Agilent Technologies, Inc. $A

Key Points

• Perbak Capital Partners LLP significantly reduced its stake in Agilent Technologies by 76.5%, selling 6,671 shares during the first quarter, leaving them with a total of 2,054 shares worth $240,000.
• Several institutional investors, including Whipplewood Advisors and Sunbelt Securities, made substantial increases in their positions, some by over 600%, indicating shifting confidence in Agilent Technologies.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Agilent, with target prices ranging from $125.00 to $150.00, reflecting positive forecasts for the company's financial growth.

Perbak Capital Partners LLP cut its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 76.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,054 shares of the medical research company's stock after selling 6,671 shares during the quarter. Perbak Capital Partners LLP's holdings in Agilent Technologies were worth $240,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Whipplewood Advisors LLC grew its position in shares of Agilent Technologies by 286.2% during the first quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company's stock valued at $29,000 after purchasing an additional 186 shares in the last quarter. Sunbelt Securities Inc. grew its position in Agilent Technologies by 640.0% in the fourth quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company's stock worth $30,000 after acquiring an additional 192 shares in the last quarter. Stone House Investment Management LLC purchased a new position in shares of Agilent Technologies during the first quarter valued at approximately $30,000. Opal Wealth Advisors LLC purchased a new position in shares of Agilent Technologies during the first quarter valued at approximately $31,000. Finally, Wood Tarver Financial Group LLC purchased a new position in shares of Agilent Technologies during the fourth quarter valued at approximately $34,000. 87.41% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the company's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the transaction, the chief executive officer directly owned 37,448 shares of the company's stock, valued at approximately $4,397,893.12. This represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.26% of the company's stock.

Agilent Technologies Stock Up 0.2%

Shares of A stock traded up $0.21 during trading hours on Friday, reaching $128.69. 1,633,203 shares of the company's stock were exchanged, compared to its average volume of 1,522,644. The stock's 50 day moving average is $119.22 and its 200-day moving average is $116.19. The company has a market cap of $36.48 billion, a price-to-earnings ratio of 30.21, a P/E/G ratio of 4.00 and a beta of 1.24. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.37. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business's quarterly revenue was up 10.1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on A. Wells Fargo & Company lifted their price target on shares of Agilent Technologies from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Thursday, August 28th. JPMorgan Chase & Co. decreased their price target on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a research note on Thursday, May 29th. UBS Group decreased their price target on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a research note on Thursday, May 29th. TD Cowen lifted their price target on shares of Agilent Technologies to $150.00 and gave the company a "buy" rating in a research note on Thursday, May 29th. Finally, Wall Street Zen downgraded shares of Agilent Technologies from a "buy" rating to a "hold" rating in a research note on Friday. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $139.25.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.